Amedeo Smart

Free Medical Literature Service

 

Amedeo

Colorectal Neoplasms
  Free Subscription

Articles published in
Clin Cancer Res
    October 2025
  1. BALLHAUSEN A, Swoboda S, Horst D, Fruehauf S, et al
    Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.
    Clin Cancer Res. 2025;31:4049-4058.
    >> Share

    September 2025
  2. SMABERS LP, Wensink GE, Verissimo CS, Doorn M, et al
    Patient-derived organoids predict treatment response in metastatic colorectal cancer.
    Clin Cancer Res. 2025 Sep 22. doi: 10.1158/1078-0432.CCR-25-1564.
    >> Share

    August 2025
  3. MICHAEL M, Wong R, Gill S, Strickland AH, et al
    The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer.
    Clin Cancer Res. 2025;31:3452-3462.
    >> Share

    June 2025
  4. MERIC-BERNSTAM F, Raghav KPS, Sweeney CJ, Swanton C, et al
    ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.
    Clin Cancer Res. 2025 Jun 13:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-2763.
    >> Share

  5. BERCZ A, Faden DL, Smith JJ, Romesser PB, et al
    Clocking Recurrence: Circulating Tumor HPV DNA Kinetics in Anal Cancer.
    Clin Cancer Res. 2025;31:2261-2263.
    >> Share

  6. MORRIS VK, Xiao W, Lin K, Wong CW, et al
    Time Dependency for Human Papillomavirus Circulating Tumor DNA Detection after Chemoradiation as a Prognostic Biomarker for Localized Anal Cancer.
    Clin Cancer Res. 2025;31:2399-2405.
    >> Share

    May 2025
  7. DREW DA, Downie JM, Chan AT
    "PIK"ing the right patients for adjuvant aspirin therapy for colorectal cancer.
    Clin Cancer Res. 2025 May 29. doi: 10.1158/1078-0432.CCR-25-0953.
    >> Share

  8. XU N, Zhang DF, Shi XX, Yang KX, et al
    Identification and Targeting of POLQ-Associated Hereditary Colorectal Cancer.
    Clin Cancer Res. 2025 May 27. doi: 10.1158/1078-0432.CCR-25-0379.
    >> Share

  9. CHRISTENSON ES, Ho WJ, Shu D, Durham JN, et al
    Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer.
    Clin Cancer Res. 2025 May 19. doi: 10.1158/1078-0432.CCR-25-0002.
    >> Share

  10. MOMEN-ROKNABADI A, Karimzadeh M, Chen NC, Cavazos TB, et al
    Detection of Early-Stage Colorectal Cancer Using Cell-Free oncRNA Biomarkers and Artificial Intelligence.
    Clin Cancer Res. 2025 May 14. doi: 10.1158/1078-0432.CCR-25-0449.
    >> Share

  11. APPLEYARD JW, Williams CJM, Manca P, Pietrantonio F, et al
    Targeting the MAP kinase pathway in colorectal cancer: A journey in personalized medicine.
    Clin Cancer Res. 2025 May 1. doi: 10.1158/1078-0432.CCR-25-0107.
    >> Share

  12. WANKHEDE D, Halama N, Kloor M, Edelmann D, et al
    Prognostic Value of CD8+ T Cells at the Invasive Margin Is Comparable to the Immune Score in Nonmetastatic Colorectal Cancer: A Prospective Multicentric Cohort Study.
    Clin Cancer Res. 2025;31:1711-1718.
    >> Share

  13. MORRIS VK, Liu S, Lin K, Zhu H, et al
    Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal.
    Clin Cancer Res. 2025;31:1657-1666.
    >> Share

    April 2025
  14. ONG JC, Zhao JJ, Liu Y, Srivastava S, et al
    Spatial heterogeneity, stromal phenotypes, and therapeutic vulnerabilities in colorectal cancer peritoneal metastasis.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-3780.
    >> Share

  15. SIRKIA O, Karjalainen H, Elomaa H, Vayrynen SA, et al
    Multimarker assessment of B cell and plasma cell subsets and their prognostic role in the colorectal cancer microenvironment.
    Clin Cancer Res. 2025 Apr 8. doi: 10.1158/1078-0432.CCR-24-4083.
    >> Share

  16. CHAUDHARY N, La Ferlita A, Choudhary BS, Jog E, et al
    Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas.
    Clin Cancer Res. 2025;31:1359-1373.
    >> Share

    March 2025
  17. LI C, Noonan AM, Hays J, Roychowdhury S, et al
    Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase 1 Clinical Trial.
    Clin Cancer Res. 2025 Mar 21. doi: 10.1158/1078-0432.CCR-24-3964.
    >> Share

  18. GULLER U, Hayoz S, Horber D, Jochum W, et al
    Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 - Prospective Randomized Placebo-Controlled Double-Blind Trial.
    Clin Cancer Res. 2025 Mar 11. doi: 10.1158/1078-0432.CCR-24-4048.
    >> Share

  19. JAZIEH K, Tsai J, Solomon S, Zhu M, et al
    Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers.
    Clin Cancer Res. 2025;31:899-906.
    >> Share

    February 2025
  20. HENRIKSEN TV, Demuth C, Frydendahl A, Nors J, et al
    Timing of circulating tumor DNA analysis aimed at guiding adjuvant treatment in colorectal cancer.
    Clin Cancer Res. 2025 Feb 20. doi: 10.1158/1078-0432.CCR-24-3200.
    >> Share

  21. SABERZADEH-ARDESTANI B, Liu Z, Stein MI, Sherman WA, et al
    Spatially resolved, multi-region proteomics for prediction of immunotherapy outcome in deficient mismatch repair metastatic colorectal cancer.
    Clin Cancer Res. 2025 Feb 19. doi: 10.1158/1078-0432.CCR-24-0853.
    >> Share

  22. SCHOENFELD JD, Azad NS, Gross J, Chen L, et al
    Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D.
    Clin Cancer Res. 2025;31:667-677.
    >> Share

  23. LIU C, Zou H, Ruan Y, Fang L, et al
    Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma.
    Clin Cancer Res. 2025;31:773-786.
    >> Share

  24. CIOMBOR KK, Bae SW, Whisenant JG, Ayers GD, et al
    Results of the phase I/II study and preliminary B cell gene signature of combined inhibition of glutamine metabolism and EGFR in colorectal cancer.
    Clin Cancer Res. 2025 Feb 10. doi: 10.1158/1078-0432.CCR-24-3133.
    >> Share

    January 2025
  25. XU C, Mannucci A, Esposito F, Oliveres H, et al
    An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.
    Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-1934.
    >> Share

  26. WEST EJ, Sadoun A, Bendjama K, Erbs P, et al
    A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer.
    Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2498.
    >> Share

    December 2024
  27. GHIDINI M, Hahne JC, Senti C, Heide T, et al
    Circulating tumor DNA dynamics and clinical outcome in metastatic colorectal cancer patients undergoing front-line chemotherapy.
    Clin Cancer Res. 2024 Dec 17. doi: 10.1158/1078-0432.CCR-24-0924.
    >> Share

  28. PIETRANTONIO F, Morano F, Niger M, Ghelardi F, et al
    The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Phase 1b/2a Trial.
    Clin Cancer Res. 2024 Dec 2. doi: 10.1158/1078-0432.CCR-24-2611.
    >> Share

    November 2024
  29. NAKAMURA Y, Kaneva K, Lo C, Neems D, et al
    A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan.
    Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-2396.
    >> Share

    October 2024
  30. MACFARLAND SP, Becktell K, Schneider KW, Kuiper RP, et al
    Pediatric Cancer Screening in Hereditary Gastrointestinal Cancer Risk Syndromes: An Update from the AACR Childhood Cancer Predisposition Working Group.
    Clin Cancer Res. 2024;30:4566-4571.
    >> Share

  31. ANDERSSON A, Escriva Conde M, Surova O, Vermeulen P, et al
    Spatial Transcriptome Mapping of the Desmoplastic Growth Pattern of Colorectal Liver Metastases by In Situ Sequencing Reveals a Biologically Relevant Zonation of the Desmoplastic Rim.
    Clin Cancer Res. 2024;30:4517-4529.
    >> Share

    September 2024
  32. LEE HM, Saw AK, Morris VK, Napolitano S, et al
    Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated colorectal cancer.
    Clin Cancer Res. 2024 Sep 13. doi: 10.1158/1078-0432.CCR-24-1166.
    >> Share

    August 2024
  33. IIDA N, Imai M, Okamoto W, Kato T, et al
    Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
    Clin Cancer Res. 2024 Aug 20:OF1-OF12. doi: 10.1158/1078-0432.CCR-24-1023.
    >> Share

  34. DAS A, MacFarland SP, Meade J, Hansford JR, et al
    Clinical Updates and Surveillance Recommendations for DNA Replication Repair Deficiency Syndromes in Children and Young Adults.
    Clin Cancer Res. 2024;30:3378-3387.
    >> Share

  35. NAKAMURA Y, Tsukada Y, Matsuhashi N, Murano T, et al
    Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay.
    Clin Cancer Res. 2024 Aug 7. doi: 10.1158/1078-0432.CCR-24-1651.
    >> Share

  36. CHANG W, Zhang Z, Jia B, Ding K, et al
    A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study.
    Clin Cancer Res. 2024;30:3337-3348.
    >> Share

    June 2024
  37. JOHANSEN AM, Forsythe SD, McGrath CT, Barker G, et al
    TGFbeta in pancreas and colorectal cancer: opportunities to overcome therapeutic resistance.
    Clin Cancer Res. 2024 Jun 25. doi: 10.1158/1078-0432.CCR-24-0468.
    >> Share

  38. LENTZ RW, Friedrich TJ, Blatchford PJ, Jordan KR, et al
    A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite stable colorectal cancer.
    Clin Cancer Res. 2024 Jun 13. doi: 10.1158/1078-0432.CCR-24-0090.
    >> Share

  39. SLATER S, Bryant A, Aresu M, Begum R, et al
    Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study.
    Clin Cancer Res. 2024 Jun 12. doi: 10.1158/1078-0432.CCR-24-0226.
    >> Share

    May 2024
  40. FUSCO MJ, Casak SJ, Mushti SL, Cheng J, et al
    FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
    Clin Cancer Res. 2024 May 29. doi: 10.1158/1078-0432.CCR-24-0281.
    >> Share

  41. VOISIN A, Terret C, Schiffler C, Bidaux AS, et al
    Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial.
    Clin Cancer Res. 2024;30:2111-2120.
    >> Share

  42. LOREE JM, Titmuss E, Topham JT, Kennecke HF, et al
    Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial.
    Clin Cancer Res. 2024 May 10. doi: 10.1158/1078-0432.CCR-24-0268.
    >> Share

  43. PARIKH AR, Chee BH, Tsai J, Rich TA, et al
    Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Clin Cancer Res. 2024 May 2. doi: 10.1158/1078-0432.CCR-23-3660.
    >> Share

  44. WU C, Pai RK, Kosiorek H, Banerjee I, et al
    Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC.
    Clin Cancer Res. 2024;30:1811-1821.
    >> Share

  45. KHUSHMAN MM, Toboni MD, Xiu J, Manne U, et al
    Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
    Clin Cancer Res. 2024;30:1906-1915.
    >> Share

    April 2024
  46. WILBUR HC, Le DT, Agarwal P
    Immunotherapy of MSI Cancer: Facts and Hopes.
    Clin Cancer Res. 2024;30:1438-1447.
    >> Share

  47. MOUILLET-RICHARD S, Cazelles A, Sroussi M, Gallois C, et al
    Clinical challenges of consensus molecular subtype CMS4 colon cancer in the era of precision medicine.
    Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-3964.
    >> Share

    March 2024
  48. HARROLD E, Keane F, Walch H, Chou JF, et al
    Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.
    Clin Cancer Res. 2024 Mar 19. doi: 10.1158/1078-0432.CCR-23-4005.
    >> Share

  49. MALVIYA G, Lannagan TRM, Johnson E, Mackintosh A, et al
    Noninvasive Stratification of Colon Cancer by Multiplex PET Imaging.
    Clin Cancer Res. 2024 Mar 17:OF1-OF12. doi: 10.1158/1078-0432.CCR-23-1063.
    >> Share

  50. STEBBING J, Bullock AJ
    Polo-like kinase 1 inhibition in KRAS-mutated metastatic colorectal cancer.
    Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-24-0251.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016